Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunsekimig long-term extension study in adults with chronic obstructive pulmonary disease after EFC18243 or EFC18244
CTR20263317Phase 3Active
- Sponsor
- Sanofi
- Start
- Sep 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of lunsekimig in chronic obstructive pulmonary disease (COPD), sponsored by Sanofi. Started Sep 2026; status: active.
02
Drugs
lunsekimig
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20263317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263317.